NCT05989672 - A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2023

Primary Completion Date

November 29, 2023

Study Completion Date

April 24, 2024

Conditions

Herpes Simplex

Interventions

BIOLOGICAL

HSVTI Formulation 1

This investigational intervention was administered intramuscularly to HSVTI\_F1 Group.

BIOLOGICAL

HSVTI Formulation 2

This investigational intervention was administered intramuscularly to HSVTI\_F2 Group.

BIOLOGICAL

Placebo

This intervention was administered intramuscularly to Placebo group.

Trial Locations (1)

GSK Investigational Site, Tokyo